The Efficacy of Rivastigmine Augementation to Antipsychotic Agents on Positive and Negative Symptoms and Quality of Life in Patients with Chronic Schizophrenia

Phase 2

Recruiting

• Conditions: Chronic schizophrenia.; Paranoid schizophrenia; F20.0

• Registration Number: IRCT20190530043769N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

All patients with Chronic Schizophrenia
Patients treated with Antipsychotics

Exclusion Criteria

Drug abuse
IQ less than 70
?Another psychiatric disorder
Physical illness
ECT in the last two weeks
Sensitivity to Rivastigmine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of Rivastigmine. Timepoint: Efficacy of Rivastigmine in three stages: at the start point, after 4 weeks and at the end of study. Method of measurement: Positive, negative symptoms questionnaire in Chronic schizophrenia patients.;Efficacy of rivastigmine. Timepoint: Efficacy of Rivastigmine in three stages: at the start point, after 4 weeks and at the end of study. Method of measurement: Quality of Life Questionnaire in Chronic schizophrenic Patients.

Secondary Outcome Measures

Name	Time	Method
Side effect. Timepoint: Two months after starting therapy. Method of measurement: Medical history and examination.